文献速递肿瘤 PET/CT

[18F]-BMS-747158-02 PET显像评估非酒精性脂肪性肝病小鼠模型肝脏线粒体复合物1功能障碍

[18F]-BMS-747158-02PET imaging for evaluating hepatic mitochondrial complex 1dysfunction in a mouse model of non-alcoholic fatty liver disease.
PubMed 文献 · EJNMMI Res · 2017-12-06

研究用[18F]-BMS-747158-02(18F-BMS)PET显像评估蛋氨酸-胆碱缺乏(MCD)饮食小鼠肝脏线粒体复合物1(MC-1)活性。雄性C57BL/6J小鼠喂饲MCD饮食至2周,于第1、2周行PET并测肝摄取(SUV)及肝匀浆MC-1活性。结果显示MCD饮食2周后肝18F-BMS摄取显著降低,30-60分钟SUV与肝MC-1活性良好相关(r=0.73,p<0.05)。

要点

  • 对照组小鼠预注射鱼藤酮后肝脏18F-BMS摄取显著受抑制,提示其与MC-1结合具有特异性。
  • MCD饮食2周后肝脏18F-BMS摄取显著降低,30-60分钟SUV与肝MC-1活性相关(r=0.73,p<0.05)。
  • MCD饮食1周和2周血浆ALT、AST升高,组织学见轻度肝脂肪变,炎症仅见于2周。

核心结论

  • 本研究表明18F-BMS是一种有潜力的PET探针,可对肝脏MC-1活性及脂肪变和炎症所致的线粒体功能障碍(如NAFLD中)进行定量显像。

研究设计与样本

  • 研究为小鼠实验,雄性C57BL/6J小鼠喂饲MCD饮食至2周,分别于第1周和第2周行18F-BMS PET扫描。
  • 18F-BMS经静脉注射,测定肝脏摄取(标准化摄取值SUV)。
  • 通过预给药鱼藤酮(特异性MC-1抑制剂)评估对MC-1的结合特异性。
  • 每次PET扫描后制备肝匀浆测定肝脏MC-1活性,并评估血液生化与组织病理学。

主要发现

  • 对照小鼠中,预注射鱼藤酮显著抑制肝脏18F-BMS摄取。
  • MCD饮食2周后18F-BMS摄取显著降低。
  • 30-60分钟SUV与肝脏MC-1活性良好相关(r=0.73,p<0.05)。
  • MCD饮食1周和2周血浆ALT和AST水平升高。
  • 组织病理学上,MCD饮食小鼠肝脏在1周和2周见轻度肝脂肪变,伴或不伴轻微炎症;炎症仅见于MCD饮食2周的小鼠。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mitochondrial dysfunction is one of the main causes of non-alcohol fatty liver disease (NAFLD). [18F]-BMS-747158-02 (18F-BMS) which was originally developed as a myocardial perfusion imaging agent was reported to bind mitochondrial complex-1 (MC-1). The aim of this study was to investigate the potential use of 18F-BMS for evaluating hepatic MC-1 activity in mice fed a methionine- and choline-deficient (MCD) diet. Male C57BL/6J mice were fed a MCD diet for up to 2 weeks. PET scans with 18F-BMS were performed after 1 and 2 weeks of the MCD diet. 18F-BMS was intravenously injected into mice, and the uptake (standardized uptake value (SUV)) in the liver was determined. The binding specificity for MC-1 was assessed by pre-administration of rotenone, a specific MC-1 inhibitor. Hepatic MC-1 activity was measured using liver homogenates generated after each positron emission tomography (PET) scan. Blood biochemistry and histopathology were also assessed. RESULTS: In control mice, hepatic 18F-BMS uptake was significantly inhibited by the pre-injection of rotenone. The uptake of 18F-BMS was significantly decreased after 2 weeks of the MCD diet. The SUV at 30-60 min was well correlated with hepatic MC-1 activity (r = 0.73, p < 0.05). Increases in plasma ALT and AST levels were also noted at 1 and 2 weeks. Mild hepatic steatosis with or without minimal inflammation was histopathologically observed at 1 and 2 weeks in mice liver on the MCD diet. However, inflammation was observed only at 2 weeks in mice on the MCD diet. CONCLUSIONS: The present study demonstrated that 18F-BMS is a potential PET probe for quantitative imaging of hepatic MC-1 activity and its mitochondrial dysfunction induced by steatosis and inflammation, such as in NAFLD.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Rokugawa T, Momosaki S, Ito M, et al. [18F]-BMS-747158-02PET imaging for evaluating hepatic mitochondrial complex 1dysfunction in a mouse model of non-alcoholic fatty liver disease. EJNMMI Res. 2017. PMID: 29209997. doi:10.1186/s13550-017-0345-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。